Results 101 to 110 of about 461 (125)

53-OR: Efficacy and Safety of Coadministered s.c. Semaglutide and s.c. Cagrilintide in Type 2 Diabetes

Diabetes, 2023
Combining sema (semaglutide 2.4 mg) and amylin analog cagri (cagrilintide 2.4 mg) has weight loss benefits, but the impact on HbA1c is unknown. This study is the first to assess the efficacy and safety of CagriSema (co-administered) vs sema or cagri alone in participants (pts) with T2D.
JUAN P. FRIAS, SRIKANTH DEENADAYALAN, LARS ERICHSEN, FILIP K. KNOP, ILDIKO LINGVAY, STANISLAVA MACURA, CHANTAL MATHIEU, SUE D. PEDERSEN, MELANIE J. DAVIES   +8 more
openaire   +1 more source

54-OR: Effect of Coadministered s.c. Semaglutide and s.c. Cagrilintide on Glycemic Levels Measured by CGM

Diabetes, 2023
Continuous glucose monitoring (CGM) offers insight into glycemic levels beyond the conventional measurement of HbA1c. This phase 2, multicenter, 32-week, double-blind trial (NCT04982575) compared the effects of CagriSema (co-administered semaglutide [sema] 2.4 mg and cagrilintide [cagri] 2.4 mg) vs sema (2.4 mg) or cagri (2.4 mg) alone, all as once ...
CHANTAL MATHIEU, SRIKANTH DEENADAYALAN, LARS ERICHSEN, JUAN P. FRIAS, FILIP K. KNOP, ILDIKO LINGVAY, EVA W. LEHMANN, SUE D. PEDERSEN, MELANIE J. DAVIES   +8 more
openaire   +1 more source

426-P: Semaglutide, Empagliflozin, and Cagrilintide Reduce Levels of Serum Endotrophin in Type 2 Diabetic Rats

Diabetes, 2023
Background: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) demonstrated cardiovascular (CV) and kidney outcomes benefit in persons with type 2 diabetes (T2D). The long-acting amylin analogue, cagrilintide, is under investigation for the treatment of obesity and T2D.
ALEXANDRA MØLLER, SIMONE A. MELANDER, ANNA T. LARSEN, CLARA F.G. LAURSEN, FEDERICA GENOVESE, MORTEN A. KARSDAL, DANIEL GULDAGER KRING RASMUSSEN, KIM HENRIKSEN   +7 more
openaire   +1 more source

#2426 Exploration of cagrilintide's mechanism of action in the kidney

Nephrology Dialysis Transplantation
Abstract Background and Aims The hormone amylin, co-secreted with insulin from the beta-cells of the pancreas, induces satiety. Previous studies have highlighted a physiological role of amylin in glucose/sodium homeostasis and blood pressure regulation.
Vera Wulfmeyer, Anja Billing, Sagar Bhayana, Mette Viberg Østergaard, Markus Rinschen   +4 more
openaire   +1 more source

Cagrilintide–Semaglutide Combination Therapy Versus Monotherapy or Placebo: A Systematic Review and Meta-Analysis

Aim: To evaluate the efficacy and safety of the fixed-dose combination of cagrilintide and semaglutide (CagriSema) compared with semaglutide, cagrilintide, or placebo in adults with overweight or obesity, integrating current evidence from randomized controlled trials Methods: We ...
Miguel Angel Samaniego Laguna, Pedro Gomes-Batista, John Cedric Mojica, Marcela Vasconcelos Montenegro, Mrunalini Dandamudi, Juan Samaniego, Alejandro Barbagelata, Juliana Giorgi   +7 more
openaire   +1 more source

Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti‐Obesity Medications: A Systematic Review, Meta‐Analysis and Meta‐Regression

Diabetes, Obesity and Metabolism
ABSTRACT Background Obesity is a complex chronic disease requiring effective long‐term management. We performed a systematic review and meta‐analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity.
Muhammad Ahmed, Muhammad Hassan, Muhammad Tahir, Muhammad Hussain, Faisal Islam, Ghulam Taha Khan, Muhammad Ahsan, Shaheer Bin Shafiq, Ahmed Ibrahim, Ammad Uddin, Saad Ahmed Waqas   +10 more
openaire   +2 more sources

849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide

Diabetes
Introduction and Objective: Non-selective amylin analogs have shown clinical weight loss benefits, though clinical incidence of nausea and vomiting are high and may require prolonged dosing titrations. Moreover, preclinical studies in rats suggest lean mass preservation versus GLP-1 receptor agonists.
DANIEL A. BRIERE, ANNE LONG, DAWN M. BULLOCK, LIBBEY O'FARRELL, BREANNA BOWEN, KATHERINE LANSU, TAMER COSKUN, JULIE S. MOYERS, HONGCHANG QU   +8 more
openaire   +1 more source

300-OR: Beneficial Effect of the Combination Therapy of Cagrilintide, a Dual Amylin/Calcitonin Agonist, and Tirzepatide, a Dual GLP-1/GIP Agonist, on Body Weight Loss in Obese Rats

Diabetes
Introduction & Objective: Combinatorial therapies with incretin receptor agonists targeting multiple pathways that regulate energy balance is a promising strategy for weight loss since it potentially allows dose reduction of each drug and can help to ameliorate the associated gastrointestinal side-effects of the current monotherapies.
PILAR VALDECANTOS, PATRICIA RADA, SOUMITRA GHOSH, CRISTINA M. RONDINONE, ANGELA M. VALVERDE   +4 more
openaire   +1 more source

1969-LB: Effect of Combined Therapy with Once-Weekly Subcutaneous Cagrilintide 2.4 mg and Semaglutide 2.4 mg (CagriSema) on Energy Intake, Gastric Emptying, and Appetite in Adults with Overweight or Obesity

Diabetes
Introduction and Objective: CagriSema is currently under development for chronic weight management and type 2 diabetes. This study characterized the effects of CagriSema on energy intake, appetite, and gastric emptying (GE) in adults with overweight or obesity.
NIKOLAJ BAK, RACHEL GA YEON LEE, ANGELA SINN, SOREN SNITKER, VALDEMAR FUNCH UHRE, EMILY WENANDE, TINE A. BÆKDAL   +6 more
openaire   +1 more source

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

Lancet, The, 2021
exaly